-
MindMed To Begin Clinical Trials On Ayahuasca's Active Ingredient DMT
Thursday, June 18, 2020 - 7:30am | 513Biopharmaceutical and psychedelics research company Mind Medicine Inc. (NEO:MMED) (OTC: MMEDF) announced Thursday that it will begin studying DMT’s effects on humans in a Phase 1 clinical trial conducted in collaboration with University Hospital Basel in Switzerland. Understanding The...
-
'Psyched': New Leaf Brands Changes Name To Mydecine, Numinus Debuts On TSXV, MindMed To Research MDMA-LSD Interactions
Saturday, June 6, 2020 - 3:15pm | 1484Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. New Leaf Brands Changes Name To Mydecine, Announces New HQ Cannabis company NewLeaf...
-
Entheon Biomedical CEO Timothy Ko On The Potential Of Psychedelics In Addiction Treatment
Tuesday, April 28, 2020 - 12:20pm | 1037Among the biggest challenges faced by the psychedelics industry is the stigma that surrounds it. "The anti-drug marketing of the past decades was highly effective, and so now when psychedelics are mentioned, visions of tie-dye come to mind," Timothy Ko told Benzinga. The times...
-
The Keys To Understanding Psilocybin's Medical Value, Market Potential
Wednesday, December 4, 2019 - 11:05am | 2355With a growing public acceptance of cannabis in society, there's a natural instinct to wonder about the possible health benefits and market potential of other still-illegal substances. “To me, all the psychedelic stuff, it's just prohibition 2.0,” Bruce Linton, cannabis...